Kwality Pharmaceuticals Ltd

Kwality Pharmaceuticals Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This measure, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, will be in effect from October 1, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter and half-year ended September 30, 2026. The specific date for the board meeting to consider these results will be communicated separately. This action is a standard procedure to prevent potential insider trading during sensitive financial reporting periods.

Kwality Pharmaceuticals Ltd. announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company reported a strong start to FY27, with consolidated revenue growing 46% year-on-year to ₹162 crore and Profit After Tax (PAT) surging 119% year-on-year to ₹26 crore. Management has raised FY27 guidance across key metrics, including revenue to over ₹700 crore. The company also advanced its R&D programs, completing 13 Bioequivalence (BE) studies and securing 15+ new product registrations. Progress was also made on the biologics front with approval to initiate pre-clinical batches for Pembrolizumab.

Kwality Pharmaceuticals posted consolidated revenue of ₹162.35 Cr in Q1FY27, up 45.6% YoY from ₹111.48 Cr and up 3.3% QoQ from ₹157.11 Cr. Consolidated PAT rose to ₹25.62 Cr from ₹11.92 Cr a year ago (+115% YoY; +1.2% QoQ), with net margin expanding to 15.7% from 10.7% YoY. No exceptional items sit in either the current or year-ago quarter, so the growth is clean/organic rather than base-effect driven. Standalone tracks consolidated almost exactly this quarter (PAT ₹25.63 Cr, EPS ₹24.70 vs consolidated EPS ₹24.69) — the foreign subsidiary contributes negligibly. The margin expansion is EBITDA-led: EBITDA rose to ₹41 Cr from ₹37 Cr YoY (+13%), with OPM widening to ~25.3% from 21.7% a year ago and 24.8% last quarter, which management attributes to operating leverage and a mix shift toward higher-margin regulated-market and oncology products rather than to lower input costs or other income (other income was flat at ₹0.62 Cr). There is no independent street coverage or consensus estimate available for this small-cap (~₹335 Cr market cap) name, so vs-street cannot be assessed; the only outside benchmark is management's own prior quarterly pacing guide of ₹150-160 Cr for Q1, which the ₹162.35 Cr print exceeds. Against the FY26-concall guidance of FY27 revenue ₹650-700 Cr and EBITDA margin 26-27%, this quarter's run-rate is tracking ahead — management used this print to raise full-year guidance to revenue ₹700+ Cr, EBITDA ₹189-196+ Cr (27-28%+ margin) and PAT ₹109+ Cr (~15.5%+ margin), i.e., the company itself signals the quarter beat its own plan. Operationally, the quarter's R&D output (13 bioequivalence studies completed toward a 40-molecule pipeline, filings live in 15+ countries) and 15+ new product registrations across Malaysia, Algeria, Peru and Mexico support the regulated-market push cited as the margin driver; CDSCO clearance for Pembrolizumab pre-clinical batches adds a second biologics candidate behind Erythropoietin, which management flagged in the prior concall as a long-term margin lever via the FY29 hormones/biologics revenue ambition. The Hormone facility remains on schedule for a November 2026 completion, the next concrete checkpoint against that plan.

Kwality Pharmaceuticals Ltd has announced that its 43rd Annual General Meeting (AGM) will be conducted on Monday, August 31, 2026, at 12:00 noon. The meeting will be held virtually through Video Conference (VC) or Other Audio Visual Means (OAVM), in compliance with directives from the Ministry of Corporate Affairs (MCA) and SEBI. This intimation serves as official notification to shareholders and for record-keeping purposes.

Kwality Pharmaceuticals Ltd's Board of Directors met on August 8, 2026, approving key decisions including the Board Report for FY26 and the Notice for the 43rd Annual General Meeting (AGM) scheduled for August 31, 2026. The company will offer e-voting via NSDL from August 28-30, 2026, with book closure from August 25-31, 2026. The Board also approved the re-appointment of Mr. Aditya Arora and Mrs. Anju Arora, who are retiring by rotation, and the regularization of Mr. Swanith Kapoor as an Independent Director. Additionally, Mr. Aditya Arora's re-appointment as Whole Time Director for five years from September 30, 2026, was approved, along with the appointment of M/s Verma Khushwinder & Co. as Cost Auditors for FY27. Mr. Rishi Mittal will serve as the Scrutinizer for the e-voting process.

Kwality Pharmaceuticals Ltd has announced that its Board of Directors will convene on August 10, 2026, to consider and approve the standalone and consolidated unaudited financial results for the quarter ending June 30, 2026. The company also confirmed that the trading window for designated persons will remain closed until 48 hours after the declaration of these financial results. The meeting is scheduled to take place at the company's registered office in Amritsar.

Kwality Pharmaceuticals Limited has received approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture pilot batches of Pembroluzimab for preclinical studies. This signifies a crucial step in the company's biologics development, moving the product from R&D to the preclinical stage. The company aims to be an early generic manufacturer of Pembroluzimab upon patent expiry of the reference product, contingent on successful development and regulatory approvals.

Kwality Pharmaceuticals Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure, effective from July 1, 2026, will last until 48 hours after the declaration of the company's unaudited financial results for the quarter ended June 30, 2026. The company is adhering to SEBI (Prohibition of Insider Trading) Regulations, 2015, and its internal code of conduct. The specific date for the board meeting to consider these financial results will be communicated separately.

Kwality Pharmaceuticals Ltd announced changes in its Board of Directors. Mr. Swanith Kapoor has been appointed as an Additional (Non-Executive, Independent) Director for a term of 5 years, subject to shareholder approval. Concurrently, Mr. Kartik Kapur has resigned as an Independent Director due to professional commitments. The company expressed appreciation for Mr. Kapur's contributions.

Kwality Pharmaceuticals Ltd announced the resignation of Mr. Kartik Kapur as an Independent Director, effective June 02, 2026, due to other professional commitments. Concurrently, the company appointed Mr. Swanith Kapoor as an Additional (Non-Executive, Independent) Director for a five-year term, subject to shareholder approval. Mr. Kapoor is a legal professional with a B.B.A. LL.B. (Hons.) and is pursuing a Master's in Business Laws.